Neuroendocrine Tumor Treatment Global Market Report 2025
상품코드:1824420
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
신경내분비종양 치료 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 10.6%로 성장할 전망이며, 35억 9,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 정밀의료의 진보, 면역 요법의 혁신, 저침습 처리, 이환율 상승, 원격 의료, 원격 진료에 기인하고 있습니다. 예측 기간 주요 동향은 진단 기술의 진보, 펩티드 수용체 방사성 핵종 요법(PRRT)의 진보, 약물 전달의 나노 기술, 새로운 방사성 의약품, 분야 횡단 협업 등이 있습니다.
향후 5년간의 성장률 10.6%라고 하는 예측은 전회 예측으로부터 0.2%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 관세 장벽은 독일과 인도에서 조달하는 Ga-68 DOTATATE PET 추적자와 Mammalian Target of Rapamycin inhibitors(mTOR) 억제제의 비용을 증가시키고 정밀 의료 옵션을 줄이며 내분비종양학의 지출을 증가시킴으로써 미국 종양학을 억제할 것으로 예측됩니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위해질 것으로 보입니다.
신경내분비종양 치료 시장의 예상 성장은 신경내분비종양(NETs)의 유병률 증가에 의해 추진될 것으로 예측됩니다. 신경내분비 세포에서 발생하는 이러한 드문 종양은 증상을 다루고, 종양의 성장을 조절하며, 표적 세포 파괴하는 방사선 요법을 이용하기 위해 필수적인 치료가 필요합니다. 주목할 점은 2023년 3월 미국 임상 종양학회(ASCO)는 미국에서는 연간 12,000명 이상이 신경내분비종양으로 진단되었고, 2023년에는 약 171,000명이 이 진단을 받으면서 생활하고 있다고 보고한 것입니다. 마찬가지로 Cancer Australia는 2022년 8월 호주에서는 2022년 5,437명이 신경내분비종양으로 진단되었으며, 그 해의 신규 사례의 3.4%를 차지했다고 밝혔습니다. 따라서 신경내분비종양의 유병률 증가는 신경내분비종양 치료 시장의 확대를 촉진하는 중요한 요인이 되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 신경내분비종양 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 신경내분비종양 치료 시장 : 성장률 분석
세계의 신경내분비종양 치료 시장 실적 : 규모 및 성장(2019-2024년)
세계의 신경내분비종양 치료 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 신경내분비종양 치료 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 신경내분비종양 치료 시장 : 제품별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
소마토스타틴 유사체(SSA)
표적 요법
화학 요법
기타 제품
세계의 신경내분비종양 치료 시장 : 적응증별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
폐
췌장
소화기계
기타 적응증
세계의 신경내분비종양 치료 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
종양학 센터
기타 최종 사용자
세계의 신경내분비종양 치료 시장 : 소마토스타틴 유사체(SSA) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
옥트레오티드
란레오티드
세계의 신경내분비종양 치료 시장 : 표적 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
티로신 키나아제 억제제(TKI)
펩티드 수용체 방사성핵종 요법(PRRT)
세계의 신경내분비종양 치료 시장 : 화학 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
종래의 화학 요법
병용 화학 요법
세계의 신경내분비종양 치료 시장 : 기타 제품 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
면역 요법
지지 요법약
제7장 지역별 및국가별 분석
세계의 신경내분비종양 치료 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 신경내분비종양 치료 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
신경내분비종양 치료 시장 : 경쟁 구도
신경내분비종양 치료 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Abbvie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Bristol-Myers Squibb Company
AstraZeneca
Takeda Pharmaceutical
Eli Lilly And Company
Amgen Inc.
Merck & Co. Inc.
Boehringer Ingelheim International GmbH
Servier
Teva Pharmaceutical Industries Ltd.
Ipsen Pharma SAS
Exelixis Inc.
Advanced Accelerator Applications SA
Hutchison Medipharma Ltd.
Tarveda Therapeutics
GlycoMira Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
신경내분비종양 치료 시장(2029년) : 새로운 기회를 제공하는 국가
신경내분비종양 치료 시장(2029년) : 새로운 기회를 제공하는 부문
신경내분비종양 치료 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Neuroendocrine tumor treatment encompasses a spectrum of medical interventions and therapies designed to effectively manage and control neuroendocrine tumors (NETs). These rare cancers originate from neuroendocrine cells responsible for regulating hormone production throughout the body. The overarching goal of neuroendocrine tumor treatment is to address tumor growth, alleviate symptoms, and enhance the overall quality of life for patients.
The primary categories of products utilized in neuroendocrine tumor treatment include somatostatin analogs (SSAs), targeted therapy, chemotherapy, and other complementary approaches. Somatostatin analogs (SSAs) are synthetic drugs engineered to replicate the actions of somatostatin, a naturally occurring hormone in the body. These analogs find application in various indications, including those affecting the lungs, pancreas, gastrointestinal system, and other relevant areas. Neuroendocrine tumor treatment products are commonly employed by medical facilities such as hospitals, oncology centers, and other healthcare institutions dedicated to providing comprehensive care for patients grappling with neuroendocrine tumors.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The neuroendocrine tumor treatment market research report is one of a series of new reports from The Business Research Company that provides neuroendocrine tumor treatment market statistics, including neuroendocrine tumor treatment industry global market size, regional shares, competitors with a neuroendocrine tumor treatment market share, detailed neuroendocrine tumor treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neuroendocrine tumor treatment industry. This neuroendocrine tumor treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The neuroendocrine tumor treatment market size has grown rapidly in recent years. It will grow from $2.17 billion in 2024 to $2.39 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to clinical research and understanding, awareness and education, specialized medical expertise, advancements in radiation therapy, and supportive care services.
The neuroendocrine tumor treatment market size is expected to see rapid growth in the next few years. It will grow to $3.59 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to precision medicine advancements, immunotherapy innovations, minimally invasive procedures, rising incidence rates, telemedicine, and remote care. Major trends in the forecast period include advancements in diagnostic technologies, peptide receptor radionuclide therapy (PRRT) advancements, nanotechnology in drug delivery, emerging radiopharmaceuticals, and cross-disciplinary collaboration.
The forecast of 10.6% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. oncology by increasing the cost of Ga-68 DOTATATE PET tracers and Mammalian Target of Rapamycin inhibitors(mTOR) inhibitors sourced from Germany and India, thereby reducing precision medicine options and elevating endocrine oncology expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated growth in the neuroendocrine tumor treatment market is expected to be propelled by the increasing prevalence of neuroendocrine tumors (NETs). These rare tumors, originating from neuroendocrine cells, necessitate essential treatment to address symptoms, control tumor growth, and utilize radiation therapy for targeted cell destruction. Notably, in March 2023, the American Society of Clinical Oncology (ASCO) reported that over 12,000 people in the United States are diagnosed with neuroendocrine tumors annually, and approximately 171,000 individuals are living with this diagnosis in 2023. Similarly, Cancer Australia, in August 2022, revealed that 5,437 people were diagnosed with neuroendocrine tumors in Australia in 2022, constituting 3.4% of all new cases for that year. The growing prevalence of neuroendocrine tumors is thus a significant driver fueling the expansion of the neuroendocrine tumor treatment market.
The growth of the neuroendocrine tumor treatment market is expected to be boosted by increasing government funding for research and development. Government funding plays a pivotal role in advancing tumor research and treatment by providing financial support for scientific studies, medical infrastructure, and enhanced access to care. This support contributes to improvements in cancer prevention, diagnosis, and overall patient outcomes. As an illustration, in September 2023, the National Cancer Institute, a US-based government agency, received a budget of $7.3 billion from the United States Congress for fiscal year 2023, representing a $408 million increase compared to the previous year. The substantial increase in government funding for research and development underscores its crucial role in driving advancements in neuroendocrine tumor treatment and contributing to the growth of the market.
Clinical drug development for neuroendocrine tumor treatment stands out as a prominent trend gaining traction in the market. Major companies within the neuroendocrine tumor treatment sector are actively engaged in developing innovative therapies to maintain their competitive positions. A noteworthy example is Viewpoint Molecular Targeting, Inc., a US-based pharmaceutical company, which, in October 2022, announced the FDA's fast-track designation for [212Pb] VMT-a-NET. This targeted alpha-particle therapy (TAT) is designed for patients with SSTR2-positive unresectable or metastatic neuroendocrine tumors (NETs). The fast-track designation by the FDA is intended to expedite the development and review process for [212Pb] VMT-a-NET, recognizing its potential to significantly improve safety or effectiveness in treating a severe condition.
Companies operating in the neuroendocrine tumor treatment market are strategically focusing on securing research funding to gain a competitive edge. Research funding, provided by various entities including government agencies, private foundations, corporations, and non-profit organizations, plays a crucial role in advancing product development and clinical trials. For instance, Ariceum Therapeutics GmbH, a Germany-based company, successfully raised EUR 25 million in June 2022 as part of its Series A financing. An additional EUR 22.75 million was raised in a Series A extension financing, supporting the further development of their lead product, Satoreotide, intended for treating low- and high-grade neuroendocrine cancers. These funds contribute to advancing Ariceum's clinical pipeline, particularly focusing on their lead radiopharmaceutical product.
In November 2022, Lantheus Holdings Inc., a US-based healthcare company specializing in diagnostic imaging products, entered into a collaboration with Point Biopharma Global Inc., a US-based radiopharmaceutical company, for a significant sum of $260 million. This collaboration aims to leverage Lantheus Holdings Inc.'s commercial expertise and global reach alongside Point Biopharma's innovative radiopharmaceutical technology. The partnership seeks to accelerate the development and commercialization of PNT2002 and PNT2003, contributing to the advancement of transformative therapies for patients with cancer, particularly in the neuroendocrine tumor treatment space.
Major companies operating in the neuroendocrine tumor treatment market include Pfizer Inc., F Hoffmann-La Roche AG, Abbvie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca, Takeda Pharmaceutical, Eli Lilly And Company, Amgen Inc., Merck & Co. Inc., Boehringer Ingelheim International GmbH, Servier, Teva Pharmaceutical Industries Ltd., Ipsen Pharma SAS, Exelixis Inc., Advanced Accelerator Applications SA, Hutchison Medipharma Ltd., Tarveda Therapeutics, GlycoMira Therapeutics Inc, AVEO Pharmaceuticals Inc., Progenics Pharmaceuticals Inc., Callisto Pharmaceuticals Pvt Ltd., Chiasma Inc.
North America was the largest region in the neuroendocrine tumor treatment market in 2024. The regions covered in the neuroendocrine tumor treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the neuroendocrine tumor treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The neuroendocrine tumor treatment market includes of revenues earned by entities by providing neuroendocrine tumor treatment services such as surgery, radiation therapy, peptide receptor radionuclide therapy, somatostatin analogs, diagnosis, staging and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Neuroendocrine Tumor Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on neuroendocrine tumor treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for neuroendocrine tumor treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neuroendocrine tumor treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
3. Neuroendocrine Tumor Treatment Market Trends And Strategies
4. Neuroendocrine Tumor Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Neuroendocrine Tumor Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Neuroendocrine Tumor Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neuroendocrine Tumor Treatment Market Growth Rate Analysis
5.4. Global Neuroendocrine Tumor Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neuroendocrine Tumor Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neuroendocrine Tumor Treatment Total Addressable Market (TAM)
6.1. Global Neuroendocrine Tumor Treatment Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Somatostatin Analogs (SSAs)
Targeted Therapy
Chemotherapy
Others Products
6.2. Global Neuroendocrine Tumor Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lungs
Pancreas
Gastrointestinal
Others Indications
6.3. Global Neuroendocrine Tumor Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Oncology Centers
Other End-Users
6.4. Global Neuroendocrine Tumor Treatment Market, Sub-Segmentation Of Somatostatin Analogs (SSAs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Octreotide
Lanreotide
6.5. Global Neuroendocrine Tumor Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tyrosine Kinase Inhibitors (TKIs)
Peptide Receptor Radionuclide Therapy (PRRT)
6.6. Global Neuroendocrine Tumor Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Traditional Chemotherapy Agents
Combination Chemotherapy Regimens
6.7. Global Neuroendocrine Tumor Treatment Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunotherapy
Supportive Care Medications
7. Neuroendocrine Tumor Treatment Market Regional And Country Analysis
7.1. Global Neuroendocrine Tumor Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neuroendocrine Tumor Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
